Evidence supporting the use of: Tauroursodeoxycholic Acid
For the health condition: Parkinson's Disease

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Tauroursodeoxycholic Acid (TUDCA) and Parkinson’s Disease: Evidence Synopsis

Tauroursodeoxycholic acid (TUDCA) is a bile acid naturally present in humans and bears, traditionally used for liver diseases. In recent years, it has attracted attention for potential neuroprotective effects in neurodegenerative diseases, including Parkinson’s Disease (PD).

Scientific Evidence: Preclinical studies have demonstrated that TUDCA may have neuroprotective effects in models of Parkinson’s Disease. In rodent and cellular models, TUDCA has been shown to reduce neuronal death, inhibit apoptosis, and protect mitochondrial function—processes highly relevant to the pathogenesis of PD. Key mechanisms include stabilization of mitochondrial membranes, reduction of oxidative stress, and suppression of endoplasmic reticulum stress.

Despite these promising findings in laboratory settings, clinical evidence in humans is extremely limited. As of June 2024, no large-scale, peer-reviewed clinical trials have conclusively demonstrated efficacy or safety of TUDCA in people with Parkinson’s Disease. Early phase studies and case reports suggest potential benefit, but these are preliminary and not sufficient to establish clinical use.

In summary, while there is a growing body of preclinical evidence supporting TUDCA’s neuroprotective effects relevant to Parkinson’s Disease, this has not yet translated into robust clinical recommendations. The current rating of 2 reflects a foundation of scientific interest and preliminary animal/lab data, but with a lack of high-quality human data.

More about Tauroursodeoxycholic Acid
More about Parkinson's Disease

Products containing Tauroursodeoxycholic Acid

We currently have no products on Vitabase that contain this ingredient.